Doctor Haoyu Wang

Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

Member of:

Department of Cardiology, Coronary Heart Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Presentations

Residual atherosclerotic risk in older patients with ASCVD: where hsCRP meets Lp(a)

Event: ESC Congress 2025

Topic: Inflammation and Immunity

Session: Old and new biomarkers and their impact on cardiovascular prognosis

Access

High-sensitivity C-Reactive protein predicts post-percutaneous coronary intervention cardiovascular risk with CKD status effect: evidence from a prospective registry study

Event: ESC Congress 2025

Topic: Inflammation and Immunity

Session: Old and new biomarkers and their impact on cardiovascular prognosis

Access

Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI

Event: ESC Congress 2021 - The Digital Experience

Topic: Outcome

Session: Highlights from the Young in Intervention

Access

New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group

Event: ESC Congress 2021 - The Digital Experience

Topic: Adjunctive Pharmacotherapy

Session: Cardiovascular intervention: patient risk and technical features

Access

Effect of risk enhancers versus technical aspects of high thrombotic risk criteria on adverse clinical events after PCI: insights from 2020 ESC NSTE-ACS Guidelines

Event: ESC Congress 2021 - The Digital Experience

Topic: Outcome

Session: Cardiovascular intervention: patient risk and technical features

Access

Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus

Event: ESC Preventive Cardiology 2021

Topic: Pharmacotherapy

Session: Young Investigators Award Secondary Prevention and Rehabilitation

Access

Usefulness of cardiometabolic index for the estimation of diabetes risk among general population in rural China: a community-based study

Event: ESC Preventive Cardiology 2021

Topic: Diabetes and the Heart

Session: Rapid fire abstracts - Primary Care and Risk Factor Management

Access

Association of a favorable cardiovascular health profile (Life's Simple 7 and Fuster-BEWAT scores) with the presence of a newly proposed 4-tiered left ventricular hypertrophy

Event: ESC Preventive Cardiology 2021

Topic: Epidemiology

Session: Rapid fire abstracts - Primary Care and Risk Factor Management

Access

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

Event: ACVC 2021

Topic: Antiplatelet Drugs

Session: Live Abstract session - Antithrombotics and bleeding

Access

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

Event: ACVC 2021

Topic: Treatment

Session: Live Abstract session - Antithrombotics and bleeding

Access

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Doctor Haoyu Wang

Biography

Contributor content

Residual atherosclerotic risk in older patients with ASCVD: where hsCRP meets Lp(a)

High-sensitivity C-Reactive protein predicts post-percutaneous coronary intervention cardiovascular risk with CKD status effect: evidence from a prospective registry study

Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI

New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group

Effect of risk enhancers versus technical aspects of high thrombotic risk criteria on adverse clinical events after PCI: insights from 2020 ESC NSTE-ACS Guidelines

Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus

Usefulness of cardiometabolic index for the estimation of diabetes risk among general population in rural China: a community-based study

Association of a favorable cardiovascular health profile (Life's Simple 7 and Fuster-BEWAT scores) with the presence of a newly proposed 4-tiered left ventricular hypertrophy

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

ESC 365 is supported by

Doctor Haoyu Wang Follow

Biography

Contributor content

Residual atherosclerotic risk in older patients with ASCVD: where hsCRP meets Lp(a)

High-sensitivity C-Reactive protein predicts post-percutaneous coronary intervention cardiovascular risk with CKD status effect: evidence from a prospective registry study

Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI

New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group

Effect of risk enhancers versus technical aspects of high thrombotic risk criteria on adverse clinical events after PCI: insights from 2020 ESC NSTE-ACS Guidelines

Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus

Usefulness of cardiometabolic index for the estimation of diabetes risk among general population in rural China: a community-based study

Association of a favorable cardiovascular health profile (Life's Simple 7 and Fuster-BEWAT scores) with the presence of a newly proposed 4-tiered left ventricular hypertrophy

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

ESC 365 is supported by

Doctor Haoyu Wang